⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 1, 1994Pharmacogenetics

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

Allan E. Rettie Larry C. Wienkers Frank J. Gonzalez William Trager Kenneth R. Korzekwa

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study investigates how the R144C variant of CYP2C9 affects the metabolism of S-warfarin, a common anticoagulant.
Analyzed the metabolic activity of S-warfarin in subjects with the R144C CYP2C9 variant.
Evaluated enzyme kinetics to determine the extent of impairment.
Included participants based on specific genotyping criteria.
Found that individuals with the R144C variant exhibit significantly reduced S-warfarin metabolism, leading to increased plasma concentrations.
Demonstrated a clear association between the R144C variant and altered anticoagulant effects, necessitating dose adjustments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Examines impaired warfarin metabolism due to CYP2C9 variant, highlighting genetic impacts on treatment effectiveness.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rettie et al. (1994) studied this question.

synapsesocial.com/papers/6a1c21b126cb5670aa9d6afd https://doi.org/10.1097/00008571-199402000-00005

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Genetic association between sensitivity to warfarin and expression of CYP2C9*3Original Research · 1997 · 303 citations
2Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapyother · 1995 · 277 citations
3Identification and Characterization of a Novel <i>Cyp2C9</i> Allelic Variant in a Warfarin-Sensitive Patientpreclinical · 2015 · 14 citations
4Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes*cross-sectional · 1998 · 183 citations
5Effect of Polymorphisms in the Cytochrome P450 CYP2C9 Gene on Warfarin Anticoagulationcase_report · 2004 · 25 citations
6Mechanistic Insights into the Effect of <i>CYP2C9*2</i> and <i>CYP2C9*3</i> Variants on the 7-Hydroxylation of Warfarinother · 2015 · 4 citations
7Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearancecross-sectional · 2002 · 343 citations
8Warfarin and Cytochrome P450 2C9 Genotype: Possible Ethnic Variation in Warfarin Sensitivitycohort · 2007 · 57 citations
9Leadership Practices of School Nutrition Professionals.Pharmacogenetics · 2007
10Response to micronized fenofibrate treatment is associated with the peroxisome???proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetesPharmacogenetics · 2004

PMore from Pharmacogenetics

More from University of Washington

More from National Institutes of Health

More from Genesis Laboratories